ADNI

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

Retrieved on: 
torsdag, mars 7, 2024
Mental Health, Neurology, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Blood, Natural history, University, Alzheimer's disease, Multimedia, Research, Pathology, News, ADAS, Conference, AFL, Patient, Disease, Psychiatry, ADNI, Dementia, MRI, Brain, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240307066794/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307066794/en/
    New 24-month data show sustained benefits across the disease spectrum from early to moderate dementia.
  • Analyses comparing the study participants to closely matched real world data and meta-analytical controls, showed significantly reduced disease progression in participants in the LUCIDITY trial.
  • In the early disease subgroup there was a significant reduction in transition to the dementia stage of AD.
  • Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.

Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia's Digital Twins to be Presented at SfN 2023

Retrieved on: 
onsdag, november 8, 2023
Alzheimer's Disease Neuroimaging Initiative, AD, Alzheimer's disease, PD, Genetic, Parkinson's disease, Parkinson, Conference, Digital twin, HIV disease progression rates, ADNI, Gene, Causal AI, Society for Neuroscience, Medical imaging, Disease, Causality (physics)

SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.

Key Points: 
  • SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.
  • The presentation will focus on results from two Digital Twins derived from The Alzheimer's Disease Neuroimaging Initiative (ADNI), The Parkinson's Progression Markers Initiative (PPMI) and Genetic cohort study.
  • Specifically, Aitia Gemini Digital Twins for AD and PD together identified 20 genes related to cytoskeleton disorganization demonstrating a potential mechanism for patient variability in disease progression.
  • Details of the abstract and poster presentation are as follow:

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Retrieved on: 
fredag, oktober 20, 2023
Science, Neurology, Radiology, Biotechnology, Research, Health, Medical Devices, Genetics, AD, Positron emission tomography, Neurodegenerative disease, MD, Party, PET, ADNI, Brain, Diagnosis, Acceleration, Medical imaging

Meilleur Technologies, Inc. today announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.

Key Points: 
  • Meilleur Technologies, Inc. today announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.
  • Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
  • The collaboration is focused on using [F-18]NAV-4694 as an imaging biomarker in ADNI4’s neurodegenerative disease research.
  • The Parties will apply [F-18]NAV-4694 imaging to aid ADNI4’s goal of a better understanding of AD to improve diagnosis and treatment of the devastating disease.

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Retrieved on: 
torsdag, september 14, 2023
Cognition, Maintenance, Blarcamesine, Magnetic resonance, University, Therapy, Alzheimer's disease, Disease, Radiology, Coronavirus Scientific Advisory Board, Medical imaging, Biomarker, Doctor of Philosophy, Dementia, Science, Plasma, MRI, DSM-IV codes, LSM, Dizziness, Amyloid, MD, UCSF, ADNI, Patient, Neurology, ADAS, Principal, Safety, Pharmaceutical industry, Medicine, Psychiatry

The trial was a Multicenter (52 medical research centers/hospitals in 5 countries), randomized, double-blind, placebo-controlled, 48-week phase 2b/3 trial that enrolled 508 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia).

Key Points: 
  • The trial was a Multicenter (52 medical research centers/hospitals in 5 countries), randomized, double-blind, placebo-controlled, 48-week phase 2b/3 trial that enrolled 508 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia).
  • Participants were randomized to receive blarcamesine (n = 338) or placebo (n = 170) oral capsules once daily for 48 weeks.
  • All prespecified clinical endpoints were analyzed using a mixed model for repeated measures (MMRM).
  • The MMRM analysis method is the convention used for regulatory filings and discussions with regulatory authorities are in preparation.

Alzheimer's Disease Mechanistic Pathways Discovered through Aitia's Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023

Retrieved on: 
onsdag, juni 28, 2023
Alzheimer's disease, Causal AI, AAIC, Bayesian network, Patient, ADNI, Digital twin, AD, Conference, Medical imaging, Disease, Causality (physics)

SOMERVILLE, Mass., June 28, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer's Disease Digital Twins  will be presented at the upcoming Alzheimer's Association International Conference (AAIC) being held from July 16-20 in Amsterdam, Netherlands.

Key Points: 
  • SOMERVILLE, Mass., June 28, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer's Disease Digital Twins  will be presented at the upcoming Alzheimer's Association International Conference (AAIC) being held from July 16-20 in Amsterdam, Netherlands.
  • Discovery of gene pathways with direct causal relationships to AD through Gemini Digital Twins of AD patients.
  • The presentation will focus on the discovery of gene pathways with direct causal relationships to Alzheimer's Disease (AD) through Gemini Digital Twins of AD patients.
  • These AD Digital Twins are created using Aitia's Causal AI and Bayesian Network platforms and multi-omic patient data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and ANMerge consortium data.

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Retrieved on: 
tisdag, april 18, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Mitt, MH, CAA, Cerebral amyloid angiopathy, Cerebral edema, AAN, Pathology, NDA, American Academy, EST, COVID, Siderosis, Inflammation, MCI, Doctor of Philosophy, Neurotoxicity, Common, Blood, Biomarker, Plasma, ARIA, Occipital bone, Amyloid, MD, ADNI, Patient, Risk, Composite, Prevalence, Oral, Microglia, AD, Safety, MMSE, Conference, Female, American Academy of Neurology, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in mid-2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Diadem Reports New Data Showing Its AlzoSure® Predict Blood Test Can Accurately Identify "Rapid Progressors" Who Will Develop Alzheimer's Disease Within Two Years

Retrieved on: 
måndag, januari 9, 2023
Dementia, Amyloid, Clinical trial, Blood, Drug development, Government budget balance, Research, Probability, Alzheimer's disease, Disease, SAN, Patient, AUC, FDA, ADNI, Diadem, AD, Diagnosis, Pharmaceutical industry, Medical imaging

MILAN and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced that its researchers have developed computational methods that enable its AlzoSure® Predict prognostic technology to accurately identify individuals who will rapidly progress to AD within two years' time. More than 95% of the patients above the new computational "cutoff" used to define "rapid progressors" were shown to progress to AD within two years' time, regardless of their baseline diagnosis. Using a modified form of the new approach, Diadem was able to do even better, accurately identifying a cohort where 100% of the patients progressed to AD within two years, while none of the patients not included in the modified cutoff cohort did so.

Key Points: 
  • The computational analysis were developed using a relatively limited number of patient samples from major international longitudinal patient databases.
  • The results will be further validated and expanded, and these analyses are already underway using global cohorts of qualified biological samples.
  • AlzoSure® Predict can allow drug developers to screen, enrich and stratify patient populations to facilitate Alzheimer's disease clinical trials.
  • Previous research also demonstrated that AlzoSure® Predict can discriminate between the different kinds of dementia with high accuracy.

TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

Retrieved on: 
torsdag, oktober 6, 2022
Disease, ADNI, Muscle atrophy, Amyloid, Cognition, Bias, Patient, Research, HIV disease progression rates, Dementia, Clinical trial, MCI, MMSE, MTC, ADAS, AD, TauRx Therapeutics, Meta-analysis, Pathology, Medical imaging, Pharmaceutical industry, Coffee, Alzheimer's disease

/PRNewswire/ -- Hydromethylthionine mesylate (HMTM) is a potent inhibitor of Tau aggregation pathology which is taken orally. The Phase 3 LUCIDITY study compared HMTM 16 mg/day with methylthioninium chloride (MTC) given at a dose of 4 mg twice weekly, the minimum required to prevent bias arising from potential urinary discolouration. The study was conducted in 598 patients with AD severity ranging from Mild Cognitive Impairment (MCI) through to the moderate stage of disease.

Key Points: 
  • It is a hallmark of the disease now generally recognised as an important potential target for treating AD.
  • TauRx has now completed the first 12-month double-blind phase of the trial.
  • All participants were required to have a positive amyloid-PET scan and not to be taking standard symptomatic treatments for AD.
  • In light of the evidence now available, TauRx does not believe that a valid blinded placebo-controlled trial of HMTM with clinical endpoints is technically feasible.

Eastern NeuroRadiology Society (ENRS 2022) – Braintale Awarded Robert D. Zimmerman Scientific Award for Widening the Usage of Its Digital Platform to Alzheimer’s Disease Patient Identification

Retrieved on: 
tisdag, augusti 23, 2022
Biotechnology, Radiology, Health, Neurology, Alzheimer's disease, Brain, Ageing, Solution, Neuroscience, ENRS, Physician, CSO, Disease, MCI, ADNI, Communication, Biomarker, MRI, White matter, Neurological disorder, DTI, Patient, Medical imaging

This is the first evidence of Braintales platform relevance to enable better care for Alzheimers disease patients, reinforced by the Robert D. Zimmerman Scientific Award granted by the scientific committee of ENRS.

Key Points: 
  • This is the first evidence of Braintales platform relevance to enable better care for Alzheimers disease patients, reinforced by the Robert D. Zimmerman Scientific Award granted by the scientific committee of ENRS.
  • Alzheimers disease and related dementia affects more than 36 million people worldwide, with more than 7 million newly diagnosed each year.
  • Braintales digital medical device platform now enables non-invasive ageing patient management in the daily clinical practice.
  • With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarkers platform to support clinical decision-making.

Embic Partners with Alzheimer's Disease Neuroimaging Initiative (ADNI) to Make Digital Cognitive Biomarkers Available to Global Alzheimer's Researchers

Retrieved on: 
onsdag, juli 27, 2022
Brain, NIH, ADNI, Digital, Dementia, Research, Biomarker, Disease, Data, Multimedia, Clinical trial, Orientation, Ageing, AD, Memory, Therapy, Cognition, Igor Grant, Population, Medical imaging, Toy, Alzheimer's disease

NEWPORT BEACH, Calif., July 27, 2022 /PRNewswire/ -- In a global effort to better understand and effectively treat Alzheimer's disease, Embic and the Alzheimer's Disease Neuroimaging Initiative (ADNI) have partnered to provide Embic's digital cognitive biomarkers to the global research community.

Key Points: 
  • NEWPORT BEACH, Calif., July 27, 2022 /PRNewswire/ -- In a global effort to better understand and effectively treat Alzheimer's disease, Embic and the Alzheimer's Disease Neuroimaging Initiative (ADNI) have partnered to provide Embic's digital cognitive biomarkers to the global research community.
  • Qualified researchers can request access to the full ADNI dataset, including Embic's seven digital biomarkers, each of which quantifies a particular cognitive process of encoding or retrieval.
  • By making these biomarkers available for researchers through ADNI, Embic will play a meaningful role in the worldwide effort to optimize cognitive health for an aging population.
  • About Embic Corporation:Embic Corporation ( www.embic.us ) is a data analytics company that develops digital biomarkers for characterizing human cognition and brain health.